Carcinoma in situ (CIS) of the bladder is a flat, high-grade urothelial cancer confined to the bladder lining. Unlike a papillary tumour that grows as a visible frond or lump, CIS can appear as a red velvety area or may be difficult to see on standard cystoscopy. It is classified as non-muscle-invasive because it has not invaded the bladder muscle, but it is biologically high risk and can progress if untreated. Standard bladder-preserving treatment is usually intravesical BCG, with close cystoscopic and cytological follow-up. Persistent BCG-unresponsive CIS may require radical cystectomy or selected alternative therapies.

Symptoms

CIS may cause urinary frequency, urgency, burning or blood in urine, but symptoms can mimic infection. Some patients have no symptoms and are diagnosed because urine cytology is abnormal or biopsies are taken during evaluation of another bladder tumour.

How CIS is diagnosed

Cystoscopy identifies suspicious mucosa, and biopsy confirms high-grade malignant cells limited to the urothelium. Urine cytology is often helpful because CIS readily sheds abnormal high-grade cells. Enhanced cystoscopy can improve detection in selected cases.

Why CIS is considered high risk

CIS may be multifocal and reflects a field change in the urothelium. Without effective treatment, it has substantial risk of recurrence and progression to muscle-invasive disease. This is why “it has not invaded muscle” should not be mistaken for “it is harmless.”

BCG treatment

Intravesical bacillus Calmette-Guérin stimulates a local immune response inside the bladder and is the standard treatment for many patients with CIS. It is usually given as an induction course followed by maintenance when tolerated and available. Response is assessed with cystoscopy, cytology and biopsy when indicated.

When cystectomy enters the discussion

If high-grade CIS persists or recurs within the BCG-unresponsive window despite adequate BCG, continuing ineffective BCG can delay curative surgery. Radical cystectomy provides the strongest oncological control; bladder-preserving alternatives may be considered for patients unfit for or refusing surgery, preferably using evidence-based protocols or trials.

CIS is invisible to patients and sometimes subtle at cystoscopy

Unlike a papillary tumour, CIS is a flat high-grade lesion. It may appear as a red velvety patch, mimic inflammation or be multifocal. Urine cytology is particularly useful because CIS sheds abnormal cells even when there is no obvious mass.

BCG is used because CIS is a field disease

Intravesical BCG treats the entire bladder lining rather than only one visible area. Induction followed by maintenance is standard for appropriate high-risk disease when tolerated. Response is assessed with cystoscopy, cytology and biopsy when indicated; symptoms alone cannot tell whether CIS has cleared.

Persistent high-grade disease after adequate BCG changes the risk-benefit balance

Once disease meets BCG-unresponsive criteria, repeatedly giving ineffective BCG can delay curative cystectomy. Bladder-preserving alternatives exist for patients unwilling or unfit for surgery, but they require an explicit discussion that oncological certainty is lower than timely radical cystectomy in a fit candidate.

CIS looks flat but behaves as high-risk disease

Bladder CIS may produce irritative urinary symptoms and can be difficult to see because it is flat rather than papillary. It is biologically high grade and can progress, so treatment usually involves BCG rather than simple observation. Persistent positive cytology with no obvious tumour may require enhanced cystoscopy, directed/random biopsies or upper-tract evaluation. Response to BCG is assessed carefully because persistent or recurrent CIS can move the discussion toward cystectomy or validated salvage strategies.

When to seek earlier medical review

Report persistent/worsening urinary frequency, pain, haematuria or fever during intravesical treatment. High fever or systemic illness after BCG requires urgent assessment. Persistent positive cytology or recurrent CIS after adequate BCG should trigger timely treatment review.

What to bring to your consultation

• TURBT/biopsy HPE
• Cytology reports
• BCG dates and number of instillations if treated
• Cystoscopy/upper-tract evaluation records

Questions to ask your doctor

• How will complete response to BCG be confirmed?
• Does my disease meet a formal BCG-unresponsive definition if it persists?
• At what point would cystectomy offer a better cure probability than further bladder-preserving treatment?

FAQs

Related reading

• Bladder Cancer: Symptoms and Treatment
• TURBT Explained
• Bladder Cancer Stages Explained: Ta, T1, T2 and Beyond
• BCG-Unresponsive Bladder Cancer: What Happens Next?
• Urologist in Latur

References

• European Association of Urology (EAU). Non-muscle-invasive Bladder Cancer Guidelines https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
• European Association of Urology (EAU). Muscle-invasive and Metastatic Bladder Cancer Guidelines. Disease Management https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/disease-management
• National Cancer Institute. Bladder Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq